ABSTRACT
The post-treatment of recycling the fine photocatalyst nanoparticles restricts their application. In this study, a new photocatalytic material was synthesized by immobilizing the N-doped TiO2 and graphene oxide (GO) composite on polypropylene (PP) (N-TiO2/GO/PP) fibre sheet, and characterized based on X-ray diffraction spectroscopy (XRD), Raman spectroscopy and Scanning Electron Microscope (SEM). The photocatalytic activity was evaluated using roxithromycin (ROX) as a typical antibiotic pollutant. XRD, Raman spectra and SEM images proved that N-TiO2/GO/PP fibre sheet was successfully synthesized. The photocatalytic degradation of 10 mgâ L-1 ROX can reach up to 90% and the degradation rate constant was 0.2299â h-1 in surface water with the application amount of TiO2/GO/PP fibre sheet of 24.6â cm × 2.7 cm and reaction time of 9 h under the irradiation of simulated sunlight. The application amount of TiO2/GO/PP fibre sheet, initial concentration of ROX and water matrix significantly affect the degradation of ROX. A low concentration of natural organic matter (NOM) slightly promoted the degradation of ROX, while a high concentration of NOM significantly inhibited the degradation of ROX. Alkaline condition (pH 8-9) is favourable for the photocatalytic degradation of ROX by TiO2/GO/PP fibre sheet. The photocatalytic reactivity of the TiO2/GO/PP fibre sheet showed no significant decrease after three runs. Two primary degradation products of ROX were identified and they showed lower ecotoxicity than ROX. The results demonstrate that the new synthesized TiO2/GO/PP fibre sheet shows promising application prospects in the treatment of antibiotics in wastewater and surface waters.
Subject(s)
Roxithromycin , Polypropylenes , Anti-Bacterial Agents , Titanium/chemistry , Water/chemistry , CatalysisABSTRACT
BackgroundNovaferon, a novel protein drug approved for the treatment of chronic hepatitis B in China, exhibits potent antiviral activities. We aimed to determine the anti-SARS-CoV-2 effects of Novaferon in vitro, and conducted a randomized, open-label, parallel group study to explore the antiviral effects of Novaferon for COVID-19. MethodsIn laboratory, the inhibition of Novaferon on viral replication in cells infected with SARS-CoV-2, and on SARS-CoV-2 entry into healthy cells was determined. Antiviral effects of Novaferon were evaluated in COVID-19 patients with treatment of Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir. The primary endpoint was the SARS-CoV-2 clearance rates on day 6 of treatment, and the secondary endpoint was the time to the SARS-CoV-2 clearance in COVID-19 patients ResultsNovaferon inhibited the viral replication in infected cells (EC50=1.02 ng/ml), and protected healthy cells from SARS-CoV-2 infection (EC50=0.1 ng/ml). Results from the 89 enrolled COVID-19 patients showed that both Novaferon and Novaferon plus Lopinavir/Ritonavir groups had significantly higher SARS-CoV-2 clearance rates on day 6 than the Lopinavir/Ritonavir group (50.0% vs.24.1%, p = 0.0400, and 60.0% vs.24.1%, p = 0.0053). Median time to SARS-CoV-2 clearance were 6 days, 6 days, and 9 days for three groups respectively, suggesting a 3-dayreduction of time to SARS-CoV-2 clearance in both Novaferon and Novaferon plus Lopinavir/Ritonavir groups compared with Lopinavir/Ritonavir group. ConclusionsNovaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justified the further evaluation of Novaferon.
ABSTRACT
<p><b>BACKGROUND AND OBJECTIVE</b>Immunocompromised patients with malignant tumor always lack of strong anti-tumor immune response, because the antigenicity of tumor cells is weak, and antigen-presenting cell function is low, so that can not be effectively presenting tumor antigens to the lymphocytes. Therefore, how to effectively induce anti-tumor immune response is the key issue. Through the study on establishing a method to culture dendritic cells (DC) in vitro and to observe the anti-lung cancer immunological effect induced by DC, we provided definite experiment basis for the clinic application of vaccine based on DC.</p><p><b>METHODS</b>Through the experiment we get the soluble antigen polypeptide from lung cancer cells GLC-82 by 3 mol/L potassium chloride. DCs are cultured and obtained from peripheral blood mononuclear cell by GM-CSF, IL-4 and TNF-a. DCs are identified by flow cytometer (FCM) and immunostaining. DCs modified by lung cancer tumor soluble antigen (TSA) and staphylococcal enterotox in A (SEA), DCs modified by TSA or DCs modified by SEA or DCs modified by nothing were cultivated together with T lymphocyte, and the obtained cells are named TSA-SEA-DCL or TSA-DCL or SEA-DCL or DCL as effector cells. The anti-tumor activity of every effector cells against target cells was assayed with MT method. Shape of DCs and effector cells, and the process of killing target cells were observed in microscope.</p><p><b>RESULTS</b>Induced DCs expressed more CD1a, CD80 and HLA-DR, which had typical cell traits such as tree branch. The killing ratio of the TSA-SEA-DCL in vitro to GLC-82 is larger than TSA-DCL, SEA-DCL and DCL, also larger than to K562. When the effector cells cultivate with target cells, we can observe the CTL approach and gather to the cancer cell, induce it necrosis and apoptosis.</p><p><b>CONCLUSION</b>Ripe DCs that have typical characteristic and phenotype could be induced successfully. High potency and relatively specific antilung caner effect can be prepared in virtue ofDC Bacterin Induced by lung caner TSA and SEA.</p>
Subject(s)
Humans , Antigens, Neoplasm , Allergy and Immunology , Cells, Cultured , Dendritic Cells , Cell Biology , Allergy and Immunology , Enterotoxins , Allergy and Immunology , Granulocyte-Macrophage Colony-Stimulating Factor , Pharmacology , Immunotherapy , Interleukin-4 , Pharmacology , Lung Neoplasms , Allergy and Immunology , Therapeutics , Superantigens , Allergy and Immunology , T-Lymphocytes, Cytotoxic , Allergy and ImmunologyABSTRACT
0.05),but the t1/2 was longer and the AUC and the Cmax were lower in group B than in other groups(P
ABSTRACT
OBJECTIVE: To study the endosomatic pharmacokinetics and bioequiavailability of kushenin tablets in health adults. METHODS: The blood concentrations of the blood samples taken from 22 healthy volunteers were determined by HPLC-MS after a single oral 0.3g kushenin (either tablet or capsule) dose and pretreatment with the internal standard (cimetidine) with m/z 265 (kushenin) taken as the detection ions and m/z 253 as the internal standard. RESULTS: The main pharmacokinetic parameters of the tablet and capsule of kushenin were as follows: t1/2 stood at (2.30?1.09)h and (1.90?0.58) h, respectively; tmax stood at (1.86?0.74)h and (1.68?0.55) h, respectively; Cmax stood at (525.09?208.94)ng/ml and (530.32?202.04) ng/ml, respectively; AUC0~11 stood at(2 048.5?749.4)(ng?h)/ml and (2 042.0?743.0)(ng?h)/ml, respectively;AUC0~∞ stood at(2 163.2?783.1)(ng?h)/ml and (2 136.4?792.1)(ng?h)/ml, respectively. The relative bioavailability of the kushenin tablet stood at (101.06?9.41) %. CONCLUSION:The tablet and capsule of kushenin were bioequiva_lent.
ABSTRACT
OBJECTIVE:To evaluate the bioequivalence of domestic secnidazole tablet,capsule and imported secnidazole tablet in healthy volunteers.METHODS:18healthy volunteers were randomly divided into3groups according to a triple-cross design,all the volunteers were given a single dose of1g secnidazole,the interval for washout period of3times adminis?tration was14days.The plasma drug concentration of secnidazole was determined by HPLC-UV.RESULTS:The main pharmacokinetic parameters of homemade tablet and homemade capsule and imported tablet were as follow,t max were(2.00?1.93),(2.67?2.14)and(1.54?1.53)h respectively,t 1/2 were(28.56?4.98)、(29.69?6.81)and(27.16?5.06)h,C max were(25.50?2.74),(24.27?3.76)and(25.64?4.10)?g/ml respectively.AUC 0~t were(736.03?73.20),(704.78?88.51)and(737.77?76.02)(?g?h)/ml respcetively.AUC 0~∞ were(886.36?114.50),(864.57?172.27)and(870.64?100.21)(?g?h)/ml respectively.The relative bioavailability of homemade tablet was(100.02?6.73)%,and that of homemade capsule was(95.91?10.66)%.CONCLUSION:3preparations of secnidazole are bioequivalent.
ABSTRACT
OBJECTIVES: To compare the effects of losartan, enalapril and their combination in the prevention of left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in the rat. METHODS: AMI model was induced in female SD rats by ligating left coronary artery. Forty-eight hours after the procedure, 83 surviving rats were randomized into one of the following 4 groups : 1) AMI control group (n = 19), 2) losartan group (n = 22, 3 mg x kg(-1) x d(-1)), 3) enalapril group (n = 20, 1 mg x kg(-1) x d(-1)), 4) losartan-enalapril combinative group (n = 22, 3 and 1 mg x kg(-1) x d(-1) respectively). 5) Sham-operated group (n = 10) and 6) normal rats group (n = 10) were selected randomly to serve as non-infarction controls. Losartan and enalapril were delivered by direct gastric gavage. After 4 weeks of medical therapy, hemodynamic studies were performed in each group, then the rat hearts were fixed with 10% formalin and pathologic analysis on them was performed. Complete experimental data was obtained in 56 rats, comprising 1) AMI controls (n = 11), 2) losartan group (n = 10), 3) enalapril group (n = 10), 4) the combination of losartan and enalapril group (n = 11), 5) sham-operated group (n = 6) and 6) normal controls (n = 8). RESULTS: There were no significant differences among the 4 AMI groups in MI size (41.7% to approximately 43.4%, all P > 0.05). Compared with sham group, the left ventricular (LV) end diastolic pressure (LVEDP), volume (LVV), long and short axis length (L and D), as well as LV absolute and relative weight (LVAW and LVRW) in AMI group were all significantly increased (P < 0.05 to approximately 0.001); whereas the maximum left ventricular pressure rising and dropping rates (+/- dp/dt) and their corrected values by LV systolic pressure (+/- dp/dt/LVSP) were significantly reduced (all P < 0.001), indicating LVRM occurred and LV systolic and diastolic function impaired after AMI. Compared with AMI group, LVEDP, LVV, LVAW and LVRW were all significantly decreased (P < 0.05 to approximately 0.001); while +/- dp/dt/LVSP were significantly enhanced in all 3 treatment groups (P < 0.05 to approximately 0.001) except -dp/dt/LVSP in losartan group (P > 0.05). There were no significant differences in the above indices among the 3 treatment groups (all P > 0.05). CONCLUSION: Both losartan and enalapril can prevent from LVRM after AMI in the rat and improve LV function with equivalent effects. There seems no additive effect when the 2 drugs are used in combination.
Subject(s)
Antihypertensive Agents/pharmacology , Enalapril/pharmacology , Losartan/pharmacology , Myocardial Infarction/physiopathology , Ventricular Remodeling/drug effects , Animals , Drug Synergism , Female , Random Allocation , Rats , Rats, Sprague-Dawley , Ventricular Function, Left/drug effectsABSTRACT
<p><b>OBJECTIVE</b>To compare the effects of high, middle and low doses of enalapril in preventing left ventricular remodeling (LVRM) after acute myocardial infarction (AMI) in rats, especially evaluating the efficacy of low dose enalapril.</p><p><b>METHODS</b>AMI was induced by ligating the left coronary artery in 149 female SD rats. 48 hours after the procedure, the 97 surviving rats were randomized to one of the following four groups: (1) AMI controls (n = 24), (2) high-dose (10 mg x kg(-1) x d(-1), n = 25), (3) middle-dose (1 mg x kg(-1) x d(-1), n = 23), and (4) low-dose (0.1 mg x kg(-1) x d(-1), n = 25) enalapril groups. In addition, sham-operated (n = 13) and normal rats (n = 10) were randomly selected to serve as non-infarction controls. Enalapril was delivered by direct gastric gavage. After 4 weeks of therapy, hemodynamic studies were performed, then the rat hearts were fixed with 10% formalin and pathology analysis was performed. Exclusive of the dead rats and those with MI size < 35% or > 55%, complete experimental data were obtained from 67 rats, which were comprised of (1) AMI controls (n = 13), (2) high-dose enalapril (n = 13), (3) middle-dose enalapril (n = 12), (4) low-dose enalapril (n = 12), (5) sham-operated (n = 8) and (6) normal (n = 9) groups.</p><p><b>RESULTS</b>There were no significant differences among the four AMI groups in infarction size (all P > 0.05). Compared with the sham-operated group, the left ventricular (LV) end diastolic pressure (LVEDP), volume (LVV), absolute and relative weight (LVAW, LVRW) in AMI group were all significantly increased (all P < 0.001), while maximum LV pressure rising and dropping rates (+/- dp/dt) and their corrected values by LV systolic pressure (+/- dp/dt/LVSP) were all significantly reduced in the AMI control group (P < 0.01 - 0.001), indicating LVRM occurred and LV systolic and diastolic functions were impaired. Compared with the AMI group, LVEDP, LVV, LVAW and LVRW were all significantly decreased in the three enalapril groups (control P < 0.001), with the reduction of LVEDP, LVV and LVAW being more significant in high-dose than in low-dose enalapril groups (all P < 0.05), and the +/- dp/dt/LVSP were significantly increased only in the high and middle-dose enalapril groups (P < 0.01).</p><p><b>CONCLUSIONS</b>High, middle and low doses of enalapril were all effective in preventing LVRM after AMI in the rat, with low dose enalapril being effective and high dose superior. As for LV functional improvement, only high and middle-dose enalapril were effective.</p>
Subject(s)
Animals , Female , Rats , Angiotensin-Converting Enzyme Inhibitors , Pharmacology , Dose-Response Relationship, Drug , Enalapril , Pharmacology , Myocardial Infarction , Rats, Sprague-Dawley , Ventricular RemodelingABSTRACT
0 05) Left ventricular (LV) end diastolic pressure (LVEDP), volume (LVV), weight (LVW) and septal thickness (STh) were all higher and left ventricular pressure maximal rate of rise and fall (?d p /d t ) were lower (all P
ABSTRACT
OBJECTIVE:To establish a method for the assaying of total flavonoids in the extracts of Gynostemma and to provide basis for the study of its internal quality.METHOD:The contents of total flavonoids in6kinds of Gynostemma made from Guangxi were determined by UV-spectrophotometry with a detection wavelength at510nm.RESULTS:Good linear re-lationship with absorbability occurred when the concentration range of rutin was0.0092~0.0553mg/ml(r=0.9999,n=6)and its average recovery was100.8%(RSD=2.25%,n=6).CONCLUSION:The method is simple and accurate,of the testing samples,Gynostemma from Guangxi ranked the first in terms of the content of total flavonoids.